Health Johnson & Johnson’s Imaavy Faces Setback in Arthritis Trial Johnson & Johnson’s newly-approved immunology treatment, Imaavy, has encountered a significant setback in its Phase 2a trial for treating rheumatoid arthritis. The trial results,... Editorial1 day ago